Vertex Pharmaceuticals (VRTX) ended the recent trading session at $402.49, demonstrating a -1.13% swing from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.55%. On ...

Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...

Different genetic mutations cause different problems with this particular protein -- so CFTR modulators generally don't work on every CF case. But Vertex's newest blockbuster, Trikafta -- approved in ...

In September, Vertex filed for Chapter 11 bankruptcy protection and accused Irving, Texas-based Matheson Tri-Gas Inc. of ...

Despite the real problems with the additional indication being sought for suzetrigine, this drop in the stock is still an ...

Vertex stock plummeted Thursday after the company's pain drug proved it's no better than a placebo in patients with lower back and hip pain.

This was the stock's third consecutive day of gains.

A member of the IBD Big Cap 20, Vertex is a top stock to consider after impressive growth last year. VERX stock could present ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $57.33, along ...

Vertex (VERX – Research Report) received a Hold rating and price target from Raymond James analyst Alexander Sklar today. The company’s ...